Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1161278 | 0.82 | MAPT (0.48) | MAPK1KDM4EL3MBTL1TP53CYP1A2 | |
| SCHEMBL23554282 | 0.81 | MAPT (0.55) | MAPK1KDM4EL3MBTL1CA12CA1 | |
| SCHEMBL29549633 | 0.81 | MAPT (0.55) | MAPK1KDM4EL3MBTL1CA12CA1 | |
| SCHEMBL26140305 | 0.81 | NPSR1 (0.50) | LCKMAPK1KDM4EL3MBTL1CA12 | |
| SCHEMBL31193217 | 0.79 | LCK (0.46) | LCKMAPK1KDM4EL3MBTL1CA12 | |
| SCHEMBL17417521 | 0.79 | LCK (0.46) | LCKMAPK1KDM4EL3MBTL1CA12 | |
| SCHEMBL12462531 | 0.79 | LCK (0.46) | LCKMAPK1CA12CA1CA2 | |
| SCHEMBL544568 | 0.79 | MAPT (0.46) | LCKMAPK1KDM4EL3MBTL1CA12 | |
| SCHEMBL31354558 | 0.79 | LCK (0.46) | LCKMAPK1CA12CA1CA2 | |
| SCHEMBL16372354 | 0.79 | LCK (0.46) | LCKMAPK1KDM4ECA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118119629-A | Nitrogen-containing heterocyclic compound and medical application thereof | 中国医药研究开发中心有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-3953360-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | HOFFMANN LA ROCHE (CH) | 2024-02-28 | — | — | EP | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| WO-2023196429-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-4141002-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-4141002-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-03-01 | — | — | EP | disclosed |
| US-11572366-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| US-11572366-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| CN-109641885-B | Heterocyclic compounds as immunomodulators | 因赛特公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20170145025-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-05-25 | — | — | US | disclosed |
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED | 2016-06-09 | — | — | US | disclosed |
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED | 2016-06-09 | — | — | US | disclosed |
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED | 2016-06-09 | — | — | US | disclosed |
| EP-3019478-A1 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| CN-105473554-A | Fused piperidine amides as modulators of ion channels | VERTEX PHARMA | 2016-04-06 | — | — | CN | disclosed |
| WO-2015006280-A9 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015006280-A9 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015006280-A1 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2015006280-A1 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | TRPV1, TRPA1, KCNJ2 | LCK 897/4885MAPK1 3344/4885KDM4E 1604/4885 |
| US-20170145025-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | LCK 112/4885MAPK1 3884/4885KDM4E 3674/4885 |
| US-11572366-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | LCK 112/4885MAPK1 3884/4885KDM4E 3674/4885 |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | LCK 3344/4885MAPK1 3649/4885KDM4E 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.